One-year Comparative evaluation of effect of emblica officinalis, Epigallactocatechin-3-gallate, chlorhexidine using selective etch technique on clinical performance of composite resin restoration in cases of Non carious cervical lesions: A randomized clinical study - NIL

开始日期2025-05-15

申办/合作机构-

ChiCTR2500101198

/ SuspendedN/AIIT

A phase III randomized controlled clinical trial of EGCG, a green tea extract, in the prevention of acute radiation-induced intestinal injury

开始日期2025-05-12

申办/合作机构

苏州大学附属第二医院

TCTR20250317007

/ Not yet recruiting临床1期IIT

Skin Evaluation of Turmeric/EGCG Emulgel for Skin Irritation and Sensitization Effects in Healthy Participants

开始日期2025-05-01

申办/合作机构

Chiang Mai University

100 项与表没食子儿茶素没食子酸酯相关的临床结果

登录后查看更多信息

100 项与表没食子儿茶素没食子酸酯相关的转化医学

登录后查看更多信息

100 项与表没食子儿茶素没食子酸酯相关的专利（医药）

登录后查看更多信息

20,501

项与表没食子儿茶素没食子酸酯相关的文献（医药）

2026-02-01·BIOMATERIALS

EGCG-releasing nanofibrous scaffold enhances wound healing via γδ T cells modulation

Article

作者: Qu, Yili ; Xu, Zhaoyu ; Yang, Xingmei ; An, Tiantian ; Li, Xinhui ; Chen, Shuaidong ; Yang, Yang ; Man, Yi ; Hu, Chen

This study investigates the role of γδ T cells in wound healing facilitated by an EGCG (Epigallocatechin gallate)-releasing nanofibrous scaffold with aligned topography (APEMS). Incorporating core-shell microcapsules for sustained EGCG release over 11 days, the biocompatible scaffold enhances γδ T cell activity to promote advanced wound repair. In a splinted wound excisional model in 6-8 weeks-old male C57BL/6J mice, APEMS significantly improved re-epithelialization and wound closure compared to a control scaffold (APS). Single-cell RNA sequencing revealed a marked increase in γδ T cell in the APEMS group, where γδ T cells accounted for 66.2 % of the T cell population, compared to 33.8 % in the APS group. Cellchat analysis identified the AREG-EGFR signaling axis as pivotal to γδ T cell-mediated wound repair. APEMS-induced γδ T cells secreted amphiregulin (AREG), which acted on keratinocytes and fibroblasts to enhance keratinocyte proliferation, migration, and fibroblast-driven extracellular matrix remodeling. In immunodeficient mice lacking mature γδ T cells (TCRδ-/-), wound healing was significantly impaired, characterized by delayed re-epithelialization, reduced neo-dermal thickness, and increased inflammation. Inhibition of AREG and EGFR function via monoclonal antibodies against AREG and EGFR antagonist Gefitinib similarly delayed wound healing, the therapeutic advantage of APEMS over APS was abolished, emphasizing its critical role in the process. These findings provide a framework for developing advanced wound management materials and highlight the therapeutic potential of targeting γδ T cells and AREG-EGFR signaling to enhance tissue regeneration.

2026-01-01·BIOMATERIALS

Metal-phenolic networks assisted construction of multi-layered endothelium-mimetic polyelectrolyte coating with nitric oxide generation and glycocalyx functionalization

Article

作者: Zhang, Chunle ; Yu, Tao ; Fu, Ping ; Chen, Chong ; Wang, Yunbing ; Xiong, Yan ; Luo, Rifang ; Qin, Yumei ; Chen, Yu

During cardiovascular-stent endothelialization, application of an endothelium-mimetic coating is desirable to establish a conducive microenvironment that promotes endothelialization, thereby reducing the risks of in-stent thrombosis and restenosis. In this study, we construct an endothelium-mimetic coating on vascular stents assisted by metal-phenolic networks (MPNs). The functional components are integrated through a layer-by-layer self-assembly technique with positively charged polyethyleneimine, negatively charged hyaluronic acid (HA), and MPNs composed of epigallocatechin gallate and Cu as a sandwiched assisting interlayer. Vasoactive nitric oxide (NO) released by Cu catalysis along with the glycocalyx major component HA modification on the surface, endow vascular stents with protective functionalities similar to that of natural endothelial cells. The presence of cation-anion electrolytes and polyphenols enhances the loading, stability, and uniformity of the coating through various interactions such as electrostatic adsorption, hydrogen bonding, π-π stacking, and covalent crosslinking of phenol-aldehyde-amine. Systematic in-vitro and in-vivo studies demonstrate that this coating significantly reduces platelet adhesion and activation and thrombus formation, selectively promotes endothelial cells proliferation and regulates the behaviour of smooth muscle cells, and mitigates inflammatory responses by the synergistic effects of NO catalytic release and glycocalyx functionalization. In-vivo stent implantation experiment reveals that, compared to bare stents, this coating accelerates stent endothelialization and inhibits intimal hyperplasia of vessels. Three months after implantation, the lumen loss rate of the coated stent is only one-third of that of the bare stent. Overall, the MPNs-assisted construction of multi-layered endothelium-mimetic polyelectrolyte coatings with a dual-modality strategy integrating contact therapy via glycocalyx functionalization and gas therapy via NO generation provides innovative insights for the development of next-generation stents. The proposed method can serve as a universal surface-modification strategy to enhance the biocompatibility of implantable cardiovascular devices.

2025-12-31·Epigenetics

An overview of potential of natural compounds to regulate epigenetic modifications in colorectal cancer: a recent update

Review

作者: Duttaroy, Asim K. ; Philip, Neha ; Pathak, Surajit ; Siripragada, Sravani ; Banerjee, Antara ; Roy, Susmita ; Deka, Dikshita ; Ayyadurai, Pavithra ; Kondaveeti, Suresh Babu

Colorectal cancer (CRC) remains an alarming global health concern despite advancements in treatment modalities over recent decades. Among the various factors contributing to CRC, this review emphasizes the critical role of epigenetic mechanisms in its pathogenesis and progression. This review also describes the potential role of natural compounds in altering the epigenetic landscape, focused mainly on DNA methylation, histone modification, and non-coding RNAs. Publications from the previous five years were searched and retrieved using well-known search engines and databases like PubMed, Google Scholar, and ScienceDirect. Keywords like CRC/colorectal cancer, CAC/Colitis associated CRC, inflammasomes, epigenetic modulation, genistein, curcumin, quercetin, resveratrol, anthocyanins, sulforaphane, and epigallocatechin-3-gallate were used in various combinations during the search. These natural compounds predominantly affect pathways such as Wnt/β-catenin, NF-κB, and PI3K/AKT to suppress CRC cell proliferation and oxidative stress and enhance anti-inflammation and apoptosis. However, their clinical use is restricted due to their low bioavailability. However, multiple methods exist to overcome challenges like this, including but not limited to structural modifications, nanoparticle encapsulations, bio-enhancers, and novel advanced delivery systems. These methods improve their potential as supportive therapies that target CRC progression epigenetically with fewer side effects. Current research focuses on enhancing epigenetic targeting to control CRC progression while minimizing side effects, emphasizing improved specificity, bioavailability, and efficacy as standalone or synergistic therapies.

项与表没食子儿茶素没食子酸酯相关的新闻（医药）

2025-07-18

·CPHI制药在线

中药汤剂自组装及其应用

关注并星标CPHI制药在线中药自组装是指中药活性成分由于非共价键力，即氢键、静电力、范德华力、π-π 堆积等相互作用，自发排列成有序结构（如纳米颗粒、纳米纤维、胶束和囊泡）的过程。研究发现，中药从生药、炮制、煎煮、制剂的成型和储存以及最终给药到体内等多个阶段都存在自组装现象。中药材含有多种不同的活性成分，包括生物碱、黄酮类化合物、多糖、挥发油、苷类、鞣质等，这些成分具有不同的药理作用和药效。它们之间的自组装行为可以发生在同种成分中，也可发生在不同成分间。如多糖类结构中含有大量的亲水基团，其可以通过氢键或疏水基团与其他结构自组装成不同复合物，进而实现药理作用的改善。蛋白质分子间自组装以弱相互作用为主，通过氢键、范德华力、静电、疏水作用等多种作用力的加合而成。三萜类化合物在自然界中广泛存在，人参、甘草、紫苏、黄芪等多种中药中都含有多种三萜的苷元及苷。三萜类化合物具有独特的手性结构、多修饰位点、良好的生物相容性和可控的降解性。三萜类化合物自组装的形成主要是通过其刚性骨架间的范德华作用以及分子间的氢键实现的。中药自组装的研究应用1、作为天然纳米载体中药汤剂自组装不仅具有人工合成纳米材料一样的药物包封能力，还具有优于人工合成纳米材料的生物可降解性、生物相容性和安全性，可以作为天然纳米载体，用于药物递送，改善药物的生物利用度，增强药物疗效。目前，苦杏仁蛋白自组装纳米颗粒、太子参蛋白自组装纳米颗粒及生姜脂质自组装纳米颗粒等已被成功用于抗肿瘤药物紫杉醇、姜黄素及多柔比星等的递送。甘草有效成分甘草酸具有两亲性，能够聚集形成自组装胶束，作为多功能药物载体被广泛用于改善药物吸收。此外，生姜脂质自组装纳米颗粒可以结肠靶向递送 siRNA 用于结肠炎的治疗，同时可能具有协同抗炎疗效；甘草蛋白自组装纳米颗粒能够包载附子毒性成分乌头碱以降低其毒性反应。2、作为抗菌材料纳米抗菌是指利用纳米技术开发的一种抗菌技术，纳米级的材料具有较大的比表面积和独特的物理、化学性质，因此在抗菌方面具有独特的优势。无机纳米银是当前研究最广泛的无机抗菌材料，其具有抑菌能力强、耐高温、安全性好等优点，但也存在产率低、造价高、毒性不确定等缺点。天然纳米抗菌剂具有抗菌性好、无毒性、绿色安全等优势，逐渐进入了人们的视野。研究发现，从芍药甘草汤中分离出的自组装纳米颗粒可以降低多种炎症因子的表达水平，减少炎性细胞浸润等，从而达到治疗银屑病小鼠的目的。天然中药提取物小檗碱与肉桂酸可以通过氢键和π-π堆积自组装形成蝶形三维结构纳米颗粒，该纳米颗粒具有良好的抑菌活性，对耐多药金黄色葡萄球菌（methicillin-resistant Staphylococcus aureus，MRSA）有较好的抑制作用，并具有更强的生物膜去除能力，其生物相容性和连续释放特性良好，毒性也较小。3、降低毒性作用甘草具有解百毒的功效，常在组方中起解毒、调和诸药的作用。《本草纲目·草部第十二卷》引甄权语："诸药中甘草为君，治七十二种乳石毒，解一千二百般草木毒，调和众药有功，故有国老之号。"甘草常与雷公藤、马钱子、附子等配伍，起到减毒的作用。研究发现，甘草和附子在煎煮过程中蛋白质会发生自组装行，通过自组装，甘草蛋白与乌头碱可形成平均粒径为（238.20±1.23）nm 的甘草蛋白-乌头碱稳定胶体颗粒。通过小鼠急性毒性实验发现，注射乌头碱单体的小鼠全部死亡，而注射相同乌头碱含量的甘草蛋白-乌头碱颗粒的小鼠全部存活，且该胶体颗粒在室温下较稳定，具有成为药物候选载体的可能性。4、增溶作用中药汤剂中包含了许多种难溶性成分，部分中药纳米自组装颗粒通过自发性的亲疏水作用或表面修饰的相互作用实现纳米粒子组装。在这个过程中，其特殊的结构特性，可以改善疏水药物的水溶性。如三萜皂苷类成分具有表面活性剂的性质，可起到增溶的作用。研究发现，甘草中三萜皂苷类成分甘草酸同时存在亲水和疏水部分，有类似表面活性剂的结构特点，可以自组装形成凝胶纳米聚集体。随着甘草酸的浓度增加，薯蓣皂苷元和齐墩果酸在水溶液中的溶解度呈上升趋势，甘草酸溶液的浓度达到 1 mmol·L⁻¹时，薯蓣皂苷元及齐墩果酸的溶解度均增加约 60倍，薯蓣皂苷元的溶解度由 6.15 ng·mL⁻¹提升到了 360.59 ng·mL⁻¹，齐墩果酸的溶解度由 20.09 ng·mL⁻¹提升到了 1155.36 ng·mL⁻¹。5、在抗肿瘤方面的研究中药自组装纳米颗粒联合化疗药物进行抗肿瘤治疗不仅可以提高化疗药物的溶解度和稳定性，还能增强其靶向和释放能力，通过不同的抗肿瘤途径达到协同增效的目的。研究发现，从苦杏仁中分离出的11S 球蛋白进行热处理时存在自组装行为，结合键类型主要以二硫键、氢键为主。在碱性环境下，蛋白质浓度越高，自组装发生的速率越快；温度越高，形成的纳米颗粒的粒径越大，且形成的纳米颗粒具有良好的低温稳定性。通过用该纳米颗粒装载抗癌药物苦杏仁苷与紫杉醇，可以提升抗癌药物对癌细胞增殖的抑制作用，对人乳腺癌细胞（human breast cancer cells，MCF-7）增殖抑制率提高了42.88%。熊果酸（ursolic acid，UA）是一种三萜类化合物，具有抗肿瘤转移、抗血管生成、抗炎和抗增殖的潜力作用，是天然植物夏枯草或铁冬青的有效成分之一。表没食子儿茶素没食子酸酯（epigallocatechin gallate，EGCG）是绿茶中含量较丰富的成分之一，具有抗肿瘤、抗氧化和心血管保护能力。 UA 与EGCG 可以通过氢键和疏水作用自组装成纳米粒，通过上皮细胞黏附分子（epithelial cell adhesion molecule，EpCAM）适配体修饰的 UA 和EGCG 的无载体、自组装的纳米药物，用于靶向荷瘤小鼠肝细胞癌（hepatocellular carcinoma，HCC）治疗，发现该自组装纳米颗粒能明显抑制肿瘤生长，且对小鼠无明显的毒性。6、揭示中药配伍机制研究中药自组装的发现有助于以新的视角揭示中药复方配伍减毒增效的作用机制。中药自组装的形成既能够包载活性成分，产生增溶及促吸收作用，增强疗效；也可以包载毒性成分，延缓或抑制毒性成分的吸收，减弱毒副作用。研究发现，葛根芩连汤自组装的形成能够促进黄芩苷的吸收及抗氧化活性；麻杏石甘汤中形成的自组装能够包载其有效成分麻黄碱和伪麻黄碱，表现出不同的细胞（Caco-2、L-02、Hep G2、NR-8383、HeLa-229）增殖抑制活性；白虎汤中形成的自组装相比其他部位（溶液或沉淀）具有更好的解热作用，与全方的解热作用一致，且具有一定的肺脑靶向性。此外，中药小分子有效成分可以参与自组装的形成，有利于其自身的吸收和细胞摄取，表现出更强的生物活性。黄连有效成分小檗碱可以与黄芩有效成分黄芩苷自组装球形成纳米粒，该自组装具有显著优于小檗碱的抗菌活性，且显示出与黄连解毒汤类似的神经细胞保护作用，这在一定程度上揭示了黄连解毒汤的配伍增效机制。7、中药新药发现新策略中药自组装的发现不仅有助于揭示中药配伍理论的科学内涵，还为中药新药的开发提供了新策略。中药汤剂自组装的形成不仅影响有效成分的吸收，还可能具有优于有效成分或其简单混合物的生物活性。如果自组装的形成只是通过促进有效成分的吸收而增强药效，则可以将有效成分分离纯化，采用新型递药技术促进有效成分的吸收，增强药效；这样能够有效避免中药物质基础复杂、作用机制不清及质控困难等问题。若是中药汤剂自组装的形成表现出显著优于有效成分或其简单混合物的生物活性，则表明自组装可能是中药及复方药效发挥的物质基础真实形态，以自组装为基础开发新药，可能具有更好的成药性，这无疑为中药新药的开发提供了一种全新的研究策略。参考资料：[1]李斌,王慧敏,刘善钊.中药汤剂自组装技术的研究进展[J].西北药学杂志,2025,40(01):225-234.[2]沈成英,胡菲,朱君君,等.中药自组装纳米粒的形成及应用研究进展[J].中国中药杂志,2021,46(19):4875-4880.作者简介：小米虫，药品质量研究工作者，长期致力于药品质量研究及药品分析方法验证工作，现就职于国内某大型药物研发公司，从事药品检验分析及分析方法验证。END来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com▼更多制药资讯，请关注CPHI制药在线▼点击阅读原文，进入智药研习社~

siRNA

2025-06-25

·EINPresswire

Altin Biosciences announces US patent approval for its first-in-class, non-hormonal, oral botanical drug candidate.

A non-surgical, non-hormonal drug that is easy to take, easy to tolerate, and preserves fertility is exactly what patients and doctors have demanded for years. Altin's drug candidate is a significant advancement to offer fibroid patients non-hormonal treatment options that go beyond merely addressing symptoms, offering a paradigm shift in fibroid treatment.” — Ayman Al-Hendy, M.D., Ph.D.,FACOG, University of Chicago EMERYVILLE, CA, UNITED STATES, June 25, 2025 / EINPresswire.com / -- Non-hormonal oral botanical uterine fibroid drug candidate receives USPTO patent approval. Altin Biosciences, a woman-founded botanical drug development company, is pleased to announce the USPTO has granted a Notice of Allowance for a Composition of Matter patent for its lead drug candidate, a non-hormonal, oral treatment for uterine fibroids. US Patent Application No. 18/115,690, titled CRILA ® AND EGCG COMPOSITIONS FOR TREATMENT OF FIBROIDS, protects Altin’s lead drug candidate, ABC-105/ABC-205. Founder and CEO, Sue McKinney, states, “ Altin's fibroid candidate meets the stated ideal for patients and doctors : easy to take, easy to tolerate, preserves fertility, and no hormones. Beyond symptomatic management, we aim to reduce or eliminate the tumors themselves. Altin’s plant-based formula, being developed under the FDA Botanical Drug Guidance, positions Altin for licensing agreements and partnership development for this novel approach to fibroid treatment. We’re pursuing FDA fast track status to meet this urgent need.” Pre-clinical studies utilizing the combination of natural compounds Crinum latifolium L var. crilae Tram & Khanh (Crila ® ) and epigallocatechin gallate (EGCG) showed apoptosis (cell death) and synergistic anti-proliferative (suppression of cell growth) effects on human fibroid cells. Dr. Ayman Al-Hendy, M.D., Ph.D., Chair of Altin Biosciences’ Medical Advisory Board, and Vice Chair for Research, Department of Obstetrics and Gynecology at University of Chicago, states: “Altin's drug candidate is a significant advancement to offer fibroid patients non-hormonal treatment options that go beyond merely addressing symptoms, offering a paradigm shift in fibroid treatment. Our study shows these natural compounds may provide a safe and cost-effective alternative to current hormonal fibroid therapies ." “Naturally occurring plant-based chemicals, like the potential drug candidate from Altin Biosciences, Crila + EGCG, is a promising drug candidate for evaluation through clinical trials for its safety and efficacy in treating gynecological conditions like uterine fibroids. Fibroids cause significant negative impact on the quality of life of women suffering from them. An effective non-hormonal intervention that reduces the fibroid size and associated symptoms would potentially alter fibroid management for millions of women in a positive manner.” Bhuchitra Singh, MD, MPH. Altin’s Chief Medical Officer and Director of Clinical Research, Department of Gynecology and Obstetrics, Division of Reproductive Sciences and Women’s Health Research, Johns Hopkins University School of Medicine. Uterine fibroids impact up to 80% of women, disproportionately impacting women of color.[1] These non-cancerous tumors cause debilitating symptoms and increase the risk of infertility, preterm delivery, post-partum hemorrhage, and anemia. Each year in the US alone, 300,000 elective hysterectomies are due to fibroids.[2] The direct and indirect annual costs associated with fibroids in the United States are $42.2 billion.[3] About Altin Biosciences Altin Biosciences is an impact-focused company in botanical drug development for unmet medical needs. Established in 2022, Altin’s lead drug candidate is backed by over 30 years of research by top scientists collaborating internationally and meets patient and physician preference for non-invasive, non-hormonal treatments that preserve fertility and reduce reliance on hysterectomy. Altin seeks to revolutionize the treatment of uterine fibroids and additional conditions, including menopause, endometriosis and prostate conditions. For more information, please visit altinbiosciences.com or write to info@altinbiosciences.com REFERENCES 1. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501-1512. doi:10.1111/1471-0528.14640 2. Stoelinga B, Huirne J, Heymans MW, Reekers JA, Ankum WM, Hehenkamp WJK. The estimated volume of the fibroid uterus: a comparison of ultrasound and bimanual examination versus volume at MRI or hysterectomy. Eur J Obstet Gynecol Reprod Biol. 2015;184:89-96. doi:10.1016/j.ejogrb.2014.11.011. 3. Hazimeh D, Coco A, Casubhoy I, Segars J, Singh B. The Annual Economic Burden of Uterine Fibroids in the United States (2010 Versus 2022): A Comparative Cost-Analysis. Reprod Sci. 2024 Dec;31(12):3743-3756. doi: 10.1007/s43032-024-01727-0. Epub 2024 Oct 25. PMID: 39455488. Sue McKinney Altin Biosciences Corporation +1 252-452-6245 suemckinney@AltinBiosciences.com Visit us on social media: LinkedIn Bluesky YouTube Dr. Ayman Al-Hendy and Altin Biosciences CEO Sue McKinney discuss the fertility-friendly potential for Altin's non-hormonal uterine fibroid drug candidate. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

快速通道

2025-06-15

·梅斯医学

喝绿茶能降血压？Blood Pressure：绿茶显著降低成人的收缩压和舒张压，且对血压升高人群效果更明显

研究概况2025年6月，权威期刊Blood Pressure在线发表了一项关于绿茶补充剂对成人血压影响的系统评价和剂量反应Meta分析研究。该研究由伊朗、美国等多国学者合作完成，纳入了36项随机对照试验（RCTs），涵盖2038名参与者，综合评估了绿茶及其提取物对收缩压（SBP）和舒张压（DBP）的调节效果。研究使用了GRADE方法评估证据质量，结合多因素亚组分析，厘清不同剂量、干预时长以及人群特征对绿茶降压效果的影响，提供了较为全面的循证医学视角。研究背景与意义高血压是心血管疾病的主要危险因素，其发病率全球上升，给公共健康带来严峻挑战。除了药物治疗，膳食干预作为低风险的辅助管理手段备受关注。绿茶以丰富的抗氧化物质，尤其是儿茶素（catechins）和表没食子儿茶素没食子酸酯（EGCG）闻名，在基础和临床研究中被多次提出具有潜在的血压调节和心血管保护作用。然而，目前临床试验结果存在异质性，且尚未明确剂量及使用时长的最优方案。为此，研究团队开展系统评价与Meta分析，纳入不同健康状态成人的RCT数据，试图解析绿茶补充对血压的总体及分类影响，并通过剂量反应分析探讨剂量与效果的相关性。研究方法简述本研究严格依照PRISMA指南进行系统文献检索（PubMed、Scopus、Web of Science，截至2024年1月），仅纳入成年人随机对照临床试验，比较绿茶补充剂与安慰剂或对照组，统一分析了前后干预期间收缩压和舒张压数据。通过随机效应模型计算加权平均差（WMD）及95%置信区间（CI），并采用亚组分析探讨潜在异质性来源。利用非线性剂量反应模型和回归分析进一步评估剂量与干预时长的影响。证据等级则借助GRADE系统进行评估。主要研究结果1. 总体效应：绿茶补充显著降低收缩压（WMD: −1.08 mmHg，95% CI: −1.98至−0.18，I²=85.0%）以及舒张压（WMD: −1.09 mmHg，95% CI: −1.67至−0.50，I²=74.0%）。进一步亚组分析（见表1）显示，以下人群绿茶降压效果更显著：基线收缩压≥120 mmHg者的收缩压降低显著（WMD: −0.84 mmHg，P=0.001）。女性（SBP WMD: −3.62 mmHg）、年轻参与者（年龄<45岁，SBP WMD: −2.06 mmHg）以及BMI<30 kg/m²的个体受益更大。干预时长≤8周、每日绿茶摄入量<500 mg、亚洲人群和采用泡饮方式的实验组亦显示较佳效果。另外，舒张压的改善同样以基线≥80 mmHg、女性、高剂量<500mg及短期干预群体为主，健康人群及单一男性组未检出明显降压效应。剂量-反应分析揭示，绿茶剂量与舒张压存在非线性相关（P-nonlinearity=0.013），但与收缩压无显著剂量反应关系（P=0.488）；干预时长与两项血压指标无显著相关性。表1. 绿茶对血压亚组分析摘要研究意义与讨论本研究系统整合并分析了大量随机对照试验数据，证实了绿茶补充剂对成人血压具有统计学上显著但临床意义较小的降低作用，平均降低约1 mmHg的收缩压及舒张压。降压效果在基线血压升高、女性、亚洲人群及短期干预中更为显著，提示个体生理状态和人种差异可能调节其响应。此外，剂量及干预时长并未表现出明确的线性关联，表明绿茶更适合作为传统降压治疗的辅助手段，而非替代选择。绿茶中的多酚类化合物（如儿茶素及EGCG）可能通过抗氧化、抗炎及调节血管内皮功能途径，促进血压改善。但考虑到影响因素复杂，现有证据仍需多中心大规模严谨设计研究予以验证与拓展。尽管降压幅度有限，但绿茶作为天然膳食补充剂，副作用低，具有在心血管危险因素管理中作为额外辅助的潜力。梅斯小编点评绿茶作为传统饮品，其丰富的生物活性成分为血压管理打开了新视角。本研究通过系统且多样的亚组与剂量响应分析，细致刻画了绿茶对不同人群血压的影响特征，具备一定的临床指导价值。未来研究可聚焦于明确绿茶活性成分的标准化配比与个体化应用，联合多指标（血管功能、生物标志物）解析作用途径，并延长干预时长以评估长期心血管预防效果。同时，探索绿茶与其他膳食及生活方式干预的协同作用，将助力精准营养干预策略的制定。参考资料：[1]Rezaei M, Akhavan N, Fathi F, et al. Effect of green tea supplementation on blood pressure in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomised controlled trials. Blood Pressure. 2025;34(1):2517122. DOI:10.1080/08037051.2025.2517122.[2]Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–237.[3]Musial C, Kuban-Jankowska A, Gorska-Ponikowska M. Beneficial properties of green tea catechins. Int J Mol Sci. 2020;21(5):1744.[4]Shafabakhsh R, Milajerdi A, Reiner Ž, et al. The effects of catechin on endothelial function: A systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2020;60(14):2369–2378.撰文 | 梅斯医学编辑 | 木白●你爱炫砂糖橘吗？研究表明：无论吃还是闻柑橘类水果，都对身体有利！吃柑橘可以起到抗抑郁的作用，而闻柑橘味则能提升认知功能●热议！湘雅二院实习医生坠亡事件引发关注，湖南联合调查组深夜发布通告！真相到底是怎样的？● 继肺癌后，喝咖啡与膀胱癌风险增加也相关？最新研究：每天3杯，不吸烟男性膀胱癌风险猛涨79%；且每天多喝一杯，肺癌风险增加6%版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

临床结果临床研究

100 项与表没食子儿茶素没食子酸酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	表没食子儿茶素没食子酸酯	-	DB12116

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
杜氏肌营养不良症	临床3期	德国	Charité - Universitätsmedizin Berlin	2010-12-30
阿尔茨海默症	临床3期	德国	Charité - Universitätsmedizin Berlin	2009-10-01
脑萎缩	临床3期	德国	-	2009-05-01
慢性进行性多发性硬化	临床3期	德国	-	2009-05-01
肝细胞癌	临床2期	美国	The University of Texas Southwestern Medical Center	2024-09-01
肝硬化	临床2期	美国	The University of Texas Southwestern Medical Center	2024-09-01
亨廷顿舞蹈病	临床2期	德国	Charité - Universitätsmedizin Berlin	2011-09-01
复发-缓解型多发性硬化	临床2期	德国	Charité - Universitätsmedizin Berlin	2007-09-01
肺动脉高压	临床前	美国	University of California, Los Angeles	2025-05-16
牙周炎	临床前	中国	遵义医科大学	2025-04-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05758571 (Pubmed) 人工标引	临床1/2期	肺炎	54	epigallocatechin-3-gallate7umol/L	鬱淵廠淵網餘繭鬱蓋糧(鹽壓繭鑰壓願範廠窪艱) = 蓋製選衊製壓醖壓觸繭鑰範網網廠築鹽鬱窪製 (構艱鬱淵獵鏇鑰獵網鬱 ) 更多	积极	2024-04-17
NCT02008721 (PROMESA, CTgov)	临床3期	多系统萎缩	92	EGCG as putative neuroprotective agent (EGCG as Putative Neuroprotective Agent)	齋構鹽積選衊鏇艱遞鑰(範範糧鑰簾鬱範觸憲鏇) = 鹹壓糧鹽製鹽遞窪積築網鹽鬱願鑰衊製鏇醖糧 (鏇夢膚艱鬱艱構窪淵壓, 1.01) 更多	-	2024-03-12
				Placebo (Placebo)	齋構鹽積選衊鏇艱遞鑰(範範糧鑰簾鬱範觸憲鏇) = 製窪製齋網鏇衊鹹膚顧網鹽鬱願鑰衊製鏇醖糧 (鏇夢膚艱鬱艱構窪淵壓, 0.99) 更多
NCT02580279 (phase II clinical study, ASTRO2023)	临床2期	乳腺癌	-	EGCG and radiotherapy	蓋衊獵壓窪蓋觸蓋夢醖(壓遞鬱鬱鹽蓋壓醖壓鹹) = 淵艱鑰襯淵襯製糧鏇襯網網壓鬱積衊顧鹹觸窪 (鏇鹽夢窪醖觸觸夢製構 ) 更多	积极	2023-10-01
				Control group (radiotherapy only)	蓋衊獵壓窪蓋觸蓋夢醖(壓遞鬱鬱鹽蓋壓醖壓鹹) = 鏇繭觸廠獵鑰窪膚範構網網壓鬱積衊顧鹹觸窪 (鏇鹽夢窪醖觸觸夢製構 ) 更多
ChiCTR2100053703 (ASTRO2023)	临床2期	盆腔肿瘤辅助	37	EGCG 400mg	範淵繭廠蓋繭構網艱醖(選廠膚夢繭築觸獵蓋鑰) = 獵鏇遞齋壓簾餘壓製繭築積獵製鹽繭製簾顧遞 (構廠鹽構糧範衊壓網膚 ) 更多	积极	2023-10-01
NCT02580279 (phase II clinical study, Pubmed \| Int J Radiat Oncol Biol Phys)	临床2期	乳腺癌	-	EGCG and radiotherapy	餘鏇選餘獵襯顧簾壓膚(鬱憲窪淵醖廠範壓簾艱) = 淵餘淵遞鬱醖顧憲窪繭積範鏇艱繭選蓋簾衊構 (網構憲餘憲蓋艱淵願廠 ) 更多	积极	2023-10-01
				Control group (radiotherapy only)	餘鏇選餘獵襯顧簾壓膚(鬱憲窪淵醖廠範壓簾艱) = 獵網鬱餘顧壓顧鑰範淵積範鏇艱繭選蓋簾衊構 (網構憲餘憲蓋艱淵願廠 ) 更多
NCT02580279 (Pubmed)	临床1期	肿瘤 \| 皮炎	19	EGCG solution	膚網網餘鏇選廠糧簾鹽(範鹽獵壓繭鹹夢鹹願壓) = significant relief can be observed in burning sensation after 15 days of EGCG treatment 鏇壓糧築衊衊鏇鬱遞糧 (選顧膚鹹顧廠壓範獵網 ) 更多	-	2023-08-24
NCT03928847 (CTgov)	早期临床1期	特发性肺纤维化	35	Epigallocatechin-3-gallate (EGCG) (EGCG PK in Healthy Volunteers 450 mg)	鏇積膚積築窪醖夢淵衊(築鏇窪網壓蓋糧築壓鹽) = 鏇夢願網廠鑰築衊襯遞積簾構鬱衊膚積夢窪範 (糧鏇鹹構繭繭鏇鬱遞窪, NA) 更多	-	2022-12-22
				Epigallocatechin-3-gallate (EGCG) (EGCG PK in Healthy Volunteers 750 mg)	鏇積膚積築窪醖夢淵衊(築鏇窪網壓蓋糧築壓鹽) = 餘簾襯壓齋範繭築廠憲積簾構鬱衊膚積夢窪範 (糧鏇鹹構繭繭鏇鬱遞窪, NA) 更多
ChiCTR2000029831 (Pubmed \| BMC Oral Health)	早期临床1期	慢性牙周炎	20	SRP plus EGCG medication	願憲簾範鏇鹹艱選簾鏇(衊鹽淵顧選遞範齋顧衊) = 鬱簾鑰鬱鹹窪齋憲鏇築夢衊糧壓網衊觸憲衊衊 (衊網夢顧願鏇繭窪齋願 ) 更多	-	2021-02-18
NCT00799890 (SUPREMES, Pubmed \| Front Neurol)	临床2/3期	慢性进行性多发性硬化	31	EGCG treated	淵淵鬱糧糧願鑰窪艱選(製淵鏇顧窪鏇襯壓鑰蓋) = 遞製鹽鑰餘顧簾衊襯鹹襯鹹糧淵構願製糧憲鹹 (衊遞蓋衊鹹構淵齋衊夢, [0.67]) 更多	-	2021-01-01
				Placebo	淵淵鬱糧糧願鑰窪艱選(製淵鏇顧窪鏇襯壓鑰蓋) = 醖艱壓憲選鬱鹹餘夢獵襯鹹糧淵構願製糧憲鹹 (衊遞蓋衊鹹構淵齋衊夢, [0.47]) 更多
NCT01928485 (CTgov)	临床2期	前列腺癌	6	active surveillance (Arm A (Active Surveillance))	網簾選鬱遞願襯鏇構顧(壓製觸獵鬱淵鬱獵網網) = 繭糧築構淵顧遞廠夢積鏇蓋願觸壓築選簾築範 (顧憲顧襯夢鬱廠襯夢繭, 2.29) 更多	-	2020-03-03
				laboratory biomarker analysis+Sunphenon (Arm B (Sunphenon))	網簾選鬱遞願襯鏇構顧(壓製觸獵鬱淵鬱獵網網) = 醖鏇鹽齋繭築網鹹鹹夢鏇蓋願觸壓築選簾築範 (顧憲顧襯夢鬱廠襯夢繭, NA) 更多